Precision Peptide closes $2M share sale under Canadian LIFE exemption
What's the deal? The Precision Peptide Company, formerly Pangea Natural FoodsDealroom has a profile for this one. Try Dealroom →, has closed a non-brokered private placement of 4,000,000 common shares at $0.50 each for gross proceeds of $2,000,000. The Vancouver-based, publicly traded wellness firm (CSE: BPC) raised the funds under Canada's Listed Issuer Financing Exemption (LIFE).
What does the company do? Precision Peptide focuses on peptide formulations and delivery systems, positioning itself at the intersection of biotechnology and consumer wellness. Its products are made in an approved US facility and distributed across North America.
Where's the money going? The company plans to use net proceeds for general working capital, to advance business objectives, fund marketing, and support inventory and product procurement. It paid no finders fees on the offering.
How does it work? The offering was made to purchasers in all Canadian provinces except Quebec, under Part 5A of National Instrument 45-106. Shares issued under the exemption carry no hold period. The securities were not registered in the US and cannot be sold to US persons absent registration or an exemption.
Why now? The raise marks a step-up from the company's previous round, signalling improved footing as it scales its wellness platform.
The signal: A no-hold-period LIFE raise is a fast, retail-friendly route for small-cap issuers to fund working capital without brokered intermediaries. For Precision Peptide, the $2 million top-up gives it near-term runway to push products and build inventory as it repositions from natural foods toward peptide-based wellness.
Read more: wallstreet-online.de
